The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting
Open accessAbstract
Many drugs are nature derived. Low drug productivity has renewed interest in natural products as drug-discovery sources. Nature-derived drugs are composed of dozens of molecular scaffolds generated by specific secondary-metabolite gene clusters in selected species. It can be hypothesized that drug-like structures probably are distributed in selective groups of species. We compared the species origins of 939 approved and 369 clinical-trial drugs with those of 119 preclinical drugs and 19,721 bioactive natural products. In contrast to the scattered distribution of bioactive natural products, these drugs are clustered into 144 of the 6,763 known species families in nature, with 80% of the approved drugs and 67% of the clinical-trial drugs concentrated in 17 and 30 drug-prolific families, respectively. Four lines of evidence from historical drug data, 13,548 marine natural products, 767 medicinal plants, and 19,721 bioactive natural products suggest that drugs are derived mostly from preexisting drug-productive families. Drug-productive clusters expand slowly by conventional technologies. The lack of drugs outside drug-productive families is not necessarily the result of under-exploration or late exploration by conventional technologies. New technologies that explore cryptic gene clusters, pathways, interspecies crosstalk, and high-throughput fermentation enable the discovery of novel natural products. The potential impact of these technologies on drug productivity and on the distribution patterns of drug-productive families is yet to be revealed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Database resources of the National Center for Biotechnology Information: update
Wheeler, D. L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh073 · Cited by 10,641
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517 · cited 9×
“First Therapeutic Target Database (24) was checked to confirm the current approval or clinical-trial status of the literature-reported approved drugs (1) and clinical-trial drugs (2, 19) of natural origin.”
BackgroundInfluentialGlobal Biodiversity: Indicators of Recent Declines
Butchart, S. H. M., Walpole, M., Collen, B., van Strien, A., Scharlemann, J. P. W., Almond, R. E. A., Baillie, J. E. M., Bomhard, B., Brown, C., Bruno, J., et al. (2010) · Science · doi:10.1126/science.1187512 · Cited by 4,892
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“During the past 2 decades, the focus of drug-discovery efforts has shifted from natural products to synthetic compounds, but this shift has not led to the anticipated increase in drug productivity (3).”
BackgroundHow many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Bioactive Microbial Metabolites: A Personal View
Bérdy, J. (2005) · The Journal of Antibiotics · doi:10.1038/ja.2005.1 · Cited by 3,170
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
Plants as a source of anti-cancer agents
Cragg, G. M., & Newman, D. J. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.05.011 · Cited by 2,034
Toward Automatic Reconstruction of a Highly Resolved Tree of Life
Ciccarelli, F. D., Doerks, T., von Mering, C., Creevey, C. J., Snel, B., & Bork, P. (2006) · Science · doi:10.1126/science.1123061 · Cited by 1,663
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Developing a new resource for drug discovery: marine actinomycete bacteria
Fenical, W., & Jensen, P. R. (2006) · Nature Chemical Biology · doi:10.1038/nchembio841 · Cited by 786
Database resources of the National Center for Biotechnology Information
Sayers, E. W., Barrett, T., Benson, D. A., Bryant, S. H., Canese, K., Chetvernin, V., Church, D. M., DiCuccio, M., Edgar, R., Federhen, S., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn741 · Cited by 768
Genomic basis for natural product biosynthetic diversity in the actinomycetes
Nett, M., Ikeda, H., & Moore, B. S. (2009) · Natural Product Reports · doi:10.1039/b817069j · Cited by 757
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Schroeckh, V., Scherlach, K., Nützmann, H.-W., Shelest, E., Schmidt-Heck, W., Schuemann, J., Martin, K., Hertweck, C., & Brakhage, A. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901870106 · Cited by 663
Marine natural products as anticancer drugs
Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597
Genomics-driven discovery of PKS-NRPS hybrid metabolites from Aspergillus nidulans
Bergmann, S., Schümann, J., Scherlach, K., Lange, C., Brakhage, A. A., & Hertweck, C. (2007) · Nature Chemical Biology · doi:10.1038/nchembio869 · Cited by 594
Triggering cryptic natural product biosynthesis in microorganisms
Scherlach, K., & Hertweck, C. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b821578b · Cited by 574
Koch, M. A., Schuffenhauer, A., Scheck, M., Wetzel, S., Casaulta, M., Odermatt, A., Ertl, P., & Waldmann, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503647102 · Cited by 544
Strategies for discovering drugs from previously unexplored natural products
Harvey, A. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01511-7 · Cited by 542
Renaissance in antibacterial discovery from actinomycetes
BALTZ, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.04.008 · Cited by 498
Phytoestrogens: a review of the present state of research
Ososki, A. L., & Kennelly, E. J. (2003) · Phytotherapy Research · doi:10.1002/ptr.1364 · Cited by 479
Plant-derived compounds in clinical trials
Saklani, A., & Kutty, S. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.010 · Cited by 477
Natural Products Version 2.0: Connecting Genes to Molecules
Walsh, C. T., & Fischbach, M. A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909118a · Cited by 468
Discovery of a new peptide natural product by Streptomyces coelicolor genome mining
Lautru, S., Deeth, R. J., Bailey, L. M., & Challis, G. L. (2005) · Nature Chemical Biology · doi:10.1038/nchembio731 · Cited by 362
Marine natural products of fungal origin
Saleem, M., Ali, M. S., Hussain, S., Jabbar, A., Ashraf, M., & Lee, Y. S. (2007) · Natural Product Reports · doi:10.1039/b607254m · Cited by 326
Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates
Duarte, C., Barreiro, E., & Fraga, C. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782331722 · Cited by 308
Assessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Update of TTD: Therapeutic Target Database
Zhu, F., Han, B., Kumar, P., Liu, X., Ma, X., Wei, X., Huang, L., Guo, Y., Han, L., Zheng, C., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp1014 · Cited by 274
Self-citationTherapies for Alzheimer's disease
Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2314 · Cited by 219
From Exotic Spice to Modern Drug?
Singh, S. (2007) · Cell · doi:10.1016/j.cell.2007.08.024 · Cited by 209
Mining and engineering natural-product biosynthetic pathways
Wilkinson, B., & Micklefield, J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.7 · Cited by 208
Fischbach, M. A., & Clardy, J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio0707-353 · Cited by 197
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.4 · Cited by 185
Self-citationMetamorphic enzyme assembly in polyketide diversification
Gu, L., Wang, B., Kulkarni, A., Geders, T. W., Grindberg, R. V., Gerwick, L. G., Håkansson, K., Wipf, P., Smith, J. L., Gerwick, W. H., et al. (2009) · Nature · doi:10.1038/nature07870 · Cited by 176
The basics of preclinical drug development for neurodegenerative disease indications
Steinmetz, K. L., & Spack, E. G. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s2 · Cited by 165
Wenzel, S. C., & Müller, R. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.08.001 · Cited by 150
Marine natural products as sources of novel scaffolds: achievement and concern
De, K., Jiang, Y., & Zhang, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.09.002 · Cited by 130
Self-citationSequence-Based Analysis of Secondary-Metabolite Biosynthesis in Marine Actinobacteria
Gontang, E. A., Gaudêncio, S. P., Fenical, W., & Jensen, P. R. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.02852-09 · Cited by 126
Drug and Drug Candidate Building Block Analysis
Wang, J., & Hou, T. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900398f · Cited by 116
Functional versus chemical diversity: is biodiversity important for drug discovery?
Tulp, M. T. M., & Bohlin, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02007-2 · Cited by 113
Evolving molecules using multi-objective optimization: applying to ADME/Tox
Ekins, S., Honeycutt, J. D., & Metz, J. T. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.04.003 · Cited by 111
Unlocking Fungal Cryptic Natural Products
Chiang, Y., Lee, K., Sanchez, J. F., Keller, N. P., & Wang, C. C. C. (2009) · Natural Product Communications · doi:10.1177/1934578x0900401113 · Cited by 105
Natural Compounds: Leads or Ideas? Bioinspired Molecules for Drug Discovery
Beghyn, T. B., Deprez-Poulain, R. F., Willand, N., Folléas, B., & Deprez, B. P. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00673.x · Cited by 95
Antiviral and Anti-inflammatory Metabolites from the Soft Coral Sinularia capillosa
Cheng, S., Huang, K., Wang, S., Wen, Z., Chen, P., & Duh, C. (2010) · Journal of Natural Products · doi:10.1021/np9008078 · Cited by 82
Comprehensive Assessment of ADMET Risks in Drug Discovery
Wang, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788682514 · Cited by 70
Neurotoxins from invertebrates as anticonvulsants: From basic research to therapeutic application
Mortari, M. R., Cunha, A. O. S., Ferreira, L. B., & dos Santos, W. F. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.009 · Cited by 64
Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2443 · Cited by 64
Distribution of the antifungal agents sordarins across filamentous fungi
Vicente, F., Basilio, Á., Platas, G., Collado, J., Bills, G. F., del Val, A. G., Martín, J., Tormo, J. R., Harris, G. H., Zink, D. L., et al. (2009) · Mycological Research · doi:10.1016/j.mycres.2009.02.011 · Cited by 53
Mining the microbial metabolome: a new frontier for natural product lead discovery
Perić, N., & Long, P. F. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02901-5 · Cited by 53
Current trends in the clinical development of peptide therapeutics.
Saladin, P. M., Zhang, B. D., & Reichert, J. M. (2009) · PubMed · Cited by 48
Pullen, C. B., Schmitz, P., Hoffmann, D., Meurer, K., Boettcher, T., von Bamberg, D., Pereira, A. M. S., França, S. D. C., Hauser, M., Geertsema, H., et al. (2003) · Phytochemistry · doi:10.1016/s0031-9422(02)00550-2 · Cited by 42
Melnikova, I. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2511 · Cited by 40
Killing two kinase families with one stone
Bilanges, B., Torbett, N. E., & Vanhaesebroeck, B. (2008) · Nature Chemical Biology · doi:10.1038/nchembio1108-648 · Cited by 30
Rediscovery of known natural compounds: nuisance or goldmine?
Tulp, M. T. M., & Bohlin, L. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.001 · Cited by 18
Cited by
Li, Y. H., Yu, C. Y., Li, X. X., Zhang, P., Tang, J., Yang, Q., Fu, T., Zhang, X., Cui, X., Tu, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1076 · Cited by 523
Self-citationKibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015) · Natural Product Reports · doi:10.1039/c5np00005j · Cited by 489
Bertrand, S., Bohni, N., Schnee, S., Schumpp, O., Gindro, K., & Wolfender, J.-L. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.03.001 · Cited by 487
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
Self-citationGenerative Adversarial Networks in Medical Image augmentation: A review
Chen, Y., Yang, X.-H., Wei, Z., Heidari, A. A., Zheng, N., Li, Z., Chen, H., Hu, H., Zhou, Q., & Guan, Q. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105382 · Cited by 414
Self-citation
Metadata
- Authors
- Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J., Tan, C., Jiang, Y., & Chen, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-07-18
- Volume
- 108
- Issue
- 31
- Pages
- 12943-12948
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2030211802
- Cited by
- 255
- References
- 58
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.